These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12709720)

  • 1. Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer.
    Wong SL; Lau DT; Baughman SA; Menchaca D; Garnick MB
    Clin Pharmacol Ther; 2003 Apr; 73(4):304-11. PubMed ID: 12709720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.
    Wong SL; Lau DT; Baughman SA; Fotheringham N; Menchaca D; Garnick MB
    J Clin Pharmacol; 2004 May; 44(5):495-502. PubMed ID: 15102870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.
    Beer TM; Ryan C; Bhat G; Garnick M;
    Anticancer Drugs; 2006 Oct; 17(9):1075-9. PubMed ID: 17001181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.
    McLeod D; Zinner N; Tomera K; Gleason D; Fotheringham N; Campion M; Garnick MB;
    Urology; 2001 Nov; 58(5):756-61. PubMed ID: 11711355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.
    Garnick MB; Campion M
    Mol Urol; 2000; 4(3):275-7. PubMed ID: 11062384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists.
    Koch M; Steidle C; Brosman S; Centeno A; Gaylis F; Campion M; Garnick MB;
    Urology; 2003 Nov; 62(5):877-82. PubMed ID: 14624912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study.
    Erb K; Pechstein B; Schueler A; Engel J; Hermann R
    Clin Pharmacol Ther; 2000 Jun; 67(6):660-9. PubMed ID: 10872648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.
    Debruyne F; Bhat G; Garnick MB
    Future Oncol; 2006 Dec; 2(6):677-96. PubMed ID: 17155895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D; Wersinger EM
    Urology; 2004 Feb; 63(2):342-7. PubMed ID: 14972486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D
    J Urol; 2003 May; 169(5):1738-41. PubMed ID: 12686821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer.
    Trachtenberg J; Gittleman M; Steidle C; Barzell W; Friedel W; Pessis D; Fotheringham N; Campion M; Garnick MB;
    J Urol; 2002 Apr; 167(4):1670-4. PubMed ID: 11912385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
    Broqua P; Riviere PJ; Conn PM; Rivier JE; Aubert ML; Junien JL
    J Pharmacol Exp Ther; 2002 Apr; 301(1):95-102. PubMed ID: 11907162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer.
    Wagner M; Garzotto M; Lemmon D; Eilers KM; Beer TM
    Urology; 2005 Apr; 65(4):799. PubMed ID: 15833548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer.
    Mongiat-Artus P; Teillac P
    Expert Opin Pharmacother; 2004 Oct; 5(10):2171-9. PubMed ID: 15461552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
    Kirby RS; Fitzpatrick JM; Clarke N
    BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.